HeyJaredAnnabel Kartal Allen
- Indexed articles, last 90 days
- 26
- Latest publication
- Sep 15, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
GSK bolsters oncology pipeline with $750m Chimagen TCE deal (opens the original)
Read excerpt
GSK has secured the rights to Chimagen Biosciences' trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company's remewed interest in oncology following a step away from the disease area a little over a decade ago. Through this agreement, GSK will secure the full global rights to the Chinese biotech's TCE programme that currently remains unnamed in exchange for an upfront fee and potential development and commercial milestone payments. While neither party has shared
Definium tees up regulatory submission for psychedelic on Phase III hat trick (opens the original)
Read excerpt
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine, DT120, following a third successful Phase III readout. The biopharma company is teeing up regulatory submissions following the positive results of the Phase III open-label Panorama study (NCT06809595), in which it pitted a 50µg and 100µg dose of its lysergic acid diethylamide (LSD)-based medicine DT120 – otherwise known as lysergide – against placebo over a 12-week perio
Apollo rumoured to be eyeing $20bn takeover of J&J’s orthopaedics business (opens the original)
Read excerpt
Alternative asset management company Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's (J&J) orthopaedics unit through a multi-billion-dollar deal. According to Bloomberg, which first shared this development, Apollo and J&J are currently in non-binding talks that could result in the former acquiring the latter's orthopaedics business, DePuy Synthes, for nearly $20bn. While anonymous sources close to the matter noted that a potential agreement could be reached within
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover (opens the original)
Read excerpt
Florida-based medtech company, Axogen has agreed to acquire BioCircuit Technologies for $200m, further bolstering its presence in the surgical peripheral nerve repair segment. Through the all-cash deal, which Axogen expects to close in Q4 2026, the medtech company will take BioCircuit's NerveTape under its wing – adding a new product to its portfolio that currently includes the Avance nerve graft system, as well as the Axoguard range of nerve connectors and protectors. This would be a notable ad
Argo points to swelling disorder drug’s differentiated profile on Phase II success (opens the original)
Read excerpt
Argo Biopharmaceutical has debuted new data from a Phase II study on its preventative therapy, BW-20805 in hereditary angioedema (HAE), that the company says highlights its "differentiated clinical profile" in this condition. Through a multi-national, open-label trial (NCT06846398), Argo set out to establish how BW-20805 acts in the body, while evaluating its potential effectiveness in reducing swelling episodes in 25 patients with HAE. According to updated data from the study, which was present
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.